Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | GEM-CESAR at EHA 2019: curative treatment strategy for high-risk smoldering myeloma

Maria-Victoria Mateos • 15 Jun 2019
EHA 2019
Multiple Myeloma Carfilzomib Dexamethasone Lenalidomide
GEM-CESAR

Maria-Victoria Mateos, MD, PhD, from the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discusses the latest news from the GEM-CESAR trial (NCT02415413) of a curative treatment strategy for high-risk smoldering myeloma: KRD as induction, followed by HDT-ASCT, KRD consolidation and maintenance with RD. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals